Physician profile
Sandeep Gupta
NPI 1336193069
$9,823.22
in general payments reported to CMS, 2019-2025
34 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,878 · 2020: $707 · 2021: $928 · 2022: $1,028 · 2023: $1,558 · 2024: $1,238 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Travel and Lodging: $350 · Consulting Fee: $26.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.04 |
| Travel and Lodging | $350.16 |
| Consulting Fee | $26.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,890.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $995.02 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $861.55 | 2019-2024 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $801.13 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $548.51 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Janssen Pharmaceuticals, INC | $513.33 | 2019-2024 | Xarelto |
| Genzyme Corporation | $498.07 | 2019-2025 | |
| Grifols USA, LLC | $452.05 | 2019-2025 | Xembify, Gamunex-C |
| Amgen INC. | $387.69 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $366.05 | 2019-2025 | Xolair |
| Abbott Laboratories | $350.16 | 2023 | Ensite |
| Pharming Healthcare, INC. | $252.55 | 2019-2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $222.49 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $203.41 | 2019-2024 | Uptravi, Opsumit |
| Biocryst US Sales Co., LLC | $191.78 | 2021-2025 | Orladeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $174.01 | 2019-2022 | |
| Blueprint Medicines Corporation | $160.96 | 2023-2025 | Ayvakit |
| Leo Pharma INC. | $146.97 | 2025 | Adbry |
| Pfizer INC. | $118.80 | 2021-2025 | |
| Optinose US, INC. | $108.07 | 2021-2024 | |
| Csl Behring | $89.56 | 2023-2025 | Hizentra, Haegarda, Privigen |
| Shire North American Group INC | $70.98 | 2019 | |
| Covis Pharma Gmbh | $65.47 | 2021-2022 | |
| Alk-Abello, INC | $65.17 | 2021-2022 | |
| Octapharma USA, INC. | $40.72 | 2022-2023 | Cutaquig |
| Biocryst Pharmaceuticals, INC. | $40.24 | 2020 | |
| Mylan Specialty L.P. | $37.34 | 2019 | |
| Azurity Pharmaceuticals, INC. | $36.65 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $36.32 | 2021-2023 | |
| Adma Biomanufacturing LLC | $26.86 | 2024 | |
| Xoran Technologies LLC | $26.67 | 2020 | |
| Greer Laboratories, INC. | $25.85 | 2024 | Palforzia |
| Hospira, INC. | $18.55 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.